EGFR and non-small cell lung carcinoma: Amivantamab exerts its therapeutic effects by suppressing EGFR and MET receptor expressions in NSCLC cells, thereby attenuating the downstream signaling pathways (Ye et al., 2021; Wang et al., 2012).